OUTLOOK 18 SEPTEMBER 2019
Accelerating flu protection
Can the latest techniques speed up the dangerously slow production of flu vaccines?
NVAX is not mentioned but the case for recombinant flu tech is made using FluBlok. It’s faster, more effective and does not require eggs. NanoFlu is basically the adjuvanted version of FluBlok. Sanofi, perhaps reluctantly, is now in P1 of FluBlok w/adjuvant. They already have market domination with FluZone & FluZone HD, now that NVAX is launching P3 with mighty Matrix-M, what choice do they have?
“The threat posed by pandemics is so great that government agencies such as BARDA might provide assistance for emerging vaccine platforms. “We’ve spent over US$6 billion on optimizing influenza vaccines, diversifying and augmenting the national supply chain,” says Bright. “We don’t think there is any pathogen on the planet that can devastate public health, lives, national security and our economic situation faster than a pandemic influenza virus.”
I’m thinking a BARDA grant for NanoFlu is in order. The new POTUS executive order dictates that companies exactly like NVAX will be getting government funding.